AS214 - Prospective cohort collaborative in pancreatic cancer epidemiology and pathogenesis (AS146 extension)

Investigator Names and Contact Information

Charles Fuchs (charles.fuchs@yale.edu)

Introduction/Intent

Introduction/Intent

Each year, 30,000 Americans die of cancer of the pancreas, making pancreatic cancer the fourth most common cause of cancer-related mortality. Nonetheless, relatively little is known about the pathogenesis and epidemiology of this malignancy. In a ongoing grant from the National Cancer Institute (Fuchs, PI, R01CA86102, WHI AS146), we are conducting analyses in pancreatic cancer using DNA and plasma from participants in the Women’s Health Initiative (WHI) in conjunction with specimens from the Nurses’ Health Study (NHS), Health Professionals Follow-up Study (HPFS), Women’s Health Study (WHS) and the Physicians’ Health Study (PHS). We wish to extend our analyses in pancreatic cancer among participants in the WHI (and the other cohorts) for the purpose of a competitive renewal of this grant. Continued pooling of cases from the ongoing prospective cohort studies will allow a rigorous examination of this important cancer. Blood specimens will be analyzed using a matched, nested case-control design of projected cases through 2007 to evaluate hypotheses focusing on mechanisms of pancreatic cancer pathogenesis. Using these resources, we propose to examine energy balance, insulin and insulin-like growth factor signaling, inflammation and H. pylori, and retinol and vitamin D-related pathways. By better understanding mechanisms, inter-relations between factors acting in similar pathways, and genetic variation, we can identify recommendations at reducing the incidence and mortality from this highly fatal malignancy.

Aims

Since pancreatic cancer is a relatively uncommon malignancy, it will be difficult for any individual prospective cohort to definitively study biochemical predictors of this disease. However, continued pooling of cases from the WHI and the other ongoing prospective cohort studies will create an unprecedented resource for the study of this important cancer. Using these resources, we propose the following specific aims:

1. Indicators of energy balance, insulin, and insulin-like growth factors (IGF)

  • a. A marker of insulin resistance and hyperinsulinemia (C-peptide; fasting insulin) is associated with higher pancreatic cancer risk whereas markers of pancreatic beta-cell dysfunction (hemoglobin A1c; pro-insulin:insulin ratio) do not predict pancreatic cancer risk.
  • b. Polymorphic variation in genes involved in the IGF and insulin pathway is associated with the risk of pancreatic cancer.
  • c. Decreased plasma adiponectin and the adiponectin (ACDC) gene T45G/G276T haplotype are associated with an increased risk of pancreatic cancer, particularly among sedentary and/or obese individuals.
  • d. Higher plasma leptin is associated with an increased risk of pancreatic cancer, independent of body mass index.

2. Inflammatory pathways:

  • a. Inflammatory markers (increased plasma C-reactive protein, interleukin-6, and tumor necrosis factor-α-receptor II) are associated with increased pancreatic cancer risk.
  • b. Genetic polymorphisms in inflammatory mediator genes are associated with the risk of pancreatic cancer. These genes include *interleukin-1-β (IL1B), interleukin-1receptor antagonist (IL1RN), interleukin-6 (IL6), interleukin-8 (IL8), interleukin-10 (IL10), tumor necrosis factor-α (TNF), transforming growth factor- β (TGFB1), peroxisome proliferator-activated receptor-g (PPARD), NFKB1, NFKBIA, NFKBIL1, COX-1 (PTGS1), and COX-2 (PTGS2). *
  • c. Helicobacter pylori colonization is associated with an increased risk of pancreatic cancer and this association is mediated, in part, by the influence of hypergastrinemia on pancreatic cancer risk.
  • d. Polymorphisms in the interleukin-1 gene cluster, TNF- α, and IL-10 augment the association between H. pylori and pancreatic cancer risk.

3. Retinol and Vitamin D

  • a. Higher levels of plasma retinol are associated with a decreased risk of pancreatic cancer and this association is modified by polymorphisms in peroxisome proliferator-activated receptor-γ.
  • b. Higher levels of plasma vitamin D are associated with a decreased risk of pancreatic cancer and this association is modified by polymorphisms in vitamin D receptor (VDR).

Results/Findings

Some of the publications related to this ancillary study are:

Ms930 - Wolpin BM, Kraft P, Gross M, Kathy Helzlsouer K, Bueno-de-Mesquita HB, Steplowski E, Stolzenberg-Solomon RZ, Arslan AA, Jacobs EJ, LaCroix A, Petersen G, Zheng W, Albanes D, Allen NE, Amundadottir L, Anderson G, Boutron-Ruault MC, Buring JE, Canzian F, Chanock SJ, Clipp S, Gaziano JM, Giovannucci EL, Hallmans G, Hankinson SE, Hoover RN, Hunter DJ, Hutchinson A, Jacobs K, Kooperberg C, Lynch SM, Mendelsohn JB, Michaud DS, Overvad K, Patel AV, Rajkovic A, Sanchéz MJ, Shu XO, Slimani N, Thomas G, Tobias GS, Trichopoulos D, Vineis P, Virtamo J, Wactawski-Wende J, Yu K, Zeleniuch-Jacquotte A, Hartge P, and Fuchs CS. Pancreatic cancer risk and ABO blood group alleles: Results from the Pancreatic Cancer Cohort Consortium. Cancer Res. 2010 Feb 1;70(3):1015-23. Epub 2010 Jan 26.

Ms936 - Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, Arslan AA, Bueno-de-Mesquita HB, Gross M, Helzlsouer K, Jacobs EJ, Lacroix A, Zheng W, Albanes D, Bamlet W, Berg CD, Berrino F, Bingham S, Buring JE, Bracci PM, Canzian F, Clavel-Chapelon F, Clipp S, Cotterchio M, de Andrade M, Duell EJ, Fox Jr JW, Gallinger S, Gaziano JM, Giovannucci EL, Goggins M, González CA, Hallmans G, Hankinson SE, Hassan M, Holly EA, Hunter DJ, Hutchinson A, Jackson R, Jacobs KB, Jenab M, Kaaks R, Klein AP, Kooperberg C, Kurtz RC, Li D, Lynch SM, Mandelson M, McWilliams RR, Mendelsohn JB, Michaud DS, Olson SH, Overvad K, Patel AV, Peeters PH, Rajkovic A, Riboli E, Risch HA, Shu XO, Thomas G, Tobias GS, Trichopoulos D, Van Den Eeden SK, Virtamo J, Wactawski-Wende J, Wolpin BM, Yu H, Yu K, Zeleniuch-Jacquotte A, Chanock SJ, Hartge P, Hoover RN. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet. 2009 Sep;41(9):986-90. Epub 2009 Aug 2.

Ms1075 - Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, Jacobs KB, Arslan AA, Bueno-de-Mesquita HB, Gallinger S, Gross M, Helzlsouer K, Holly EA, Jacobs EJ, Klein AP, Lacroix A, Li D, Mandelson MT, Olson SH, Risch HA, Zheng W, Albanes D, Bamlet WR, Berg CD, Boutron-Ruault MC, Buring JE, Bracci PM, Canzian F, Clipp S, Cotterchio M, de Andrade M, Duell EJ, Gaziano JM, Giovannucci EL, Goggins M, Hallmans G, Hankinson SE, Hassan M, Howard B, Hunter DJ, Hutchinson A, Jenab M, Kaaks R, Kooperberg C, Krogh V, Kurtz RC, Lynch SM, McWilliams RR, Mendelsohn JB, Michaud DS, Parikh H, Patel AV, Peeters PH, Rajkovic A, Riboli E, Rodriguez L, Seminara D, Shu XO, Thomas G, Tjønneland A, Tobias GS, Trichopoulos D, Van Den Eeden SK, Virtamo J, Wactawski-Wende J, Wang Z, Wolpin BM, Yu H, Yu K, Zeleniuch-Jacquotte A, Fraumeni JF Jr, Hoover RN, Hartge P, Chanock SJ. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet. 2010 Mar;42(3):224-8. Epub 2010 Jan 24

Ms1182 - Wolpin BM, Ng K, Bao Y, Kraft P, Stampfer MJ, Michaud DS, Ma J, Buring JE, Sesso H, Lee IM, Rifai N, Cochrane BB, Wactawaski-Wende J, Chlebowski RT, Willett WC, Manson JE, Giovannucci EL, Fuchs CS. Plasma 25-Hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):82-91. Epub 2011 Nov 15

Ms1408 - Bao Y, Giovannucci EL, Kraft P, Stampfer MJ, Ogino S, Ma J, Buring JE, Sesso HD, Lee IM, Gaziano JM, Rifai N, Pollak MN, Cochrane BB, Kaklamani V, Lin JH, Manson JE, Fuchs CS, Wolpin BM. A prospective study of plasma adiponectin and pancreatic cancer risk in 5 US Cohorts. J Natl Cancer Inst. 2013 Jan 16;105(2):95-103. doi: 10.1093/jnci/djs474. Epub 2012 Dec 14

For a complete, up-to-date list of WHI papers related to this ancillary study, please use the searchable Bibliography section of this website. To search for papers by study number, access the Simple Search, and enter the study number in the “Related Studies” field.

Data Dictionaries and Study Documentation

This section displays all study-related data dictionaries and study-related files. The investigators for this study will upload the datasets, data dictionaries, and other study-related files. Study-related files will be made available to the public one year after the completion of the ancillary study, with the exception of the datasets, which will only be available to those with a Data Distribution Agreement. Those will be available to those with permission to download and will appear as a download link next to the data dictionary

Data Dictionaries

Name
Description
No results found

Study Documents

Name
Description
NameAS214_selection criteria.pdfDescription

Related Papers

Evaluation of the association between circulating IL-1β and related cytokines and incident atrial fibrillation in a cohort of postmenopausal women

Marco Perez et al., 2023/1 PubMed #36646198 MSID: 2432
Background: Inflammatory cytokines play a role in atrial fibrillation (AF). Interleukin (IL)-1β, which is targeted in the treatment of ischemic heart disease, has not been well-studied in relation to AF. Methods: Postmenopausal women from the Women's Health Initiative were included. Cox proportional hazards regression models were used to evaluate the association between log-transformed baseline cytokine levels and future AF incidence. Models were adjusted for body mass index, age, race, educatio...
Keywords: Atrial Fibrillation; Myocytokines; Il-6; Crp; Biomarkers; Inflammation

Pancreatic cancer risk and ABO blood group alleles: Results from the Pancreatic Cancer Cohort Consortium

Brian Wolpin et al., 2010/1 PubMed #20103627 MSID: 930
A recent genome-wide association study (PanScan) identified significant associations at the ABO gene locus with risk of pancreatic cancer, but the influence of specific ABO genotypes remains unknown. We determined ABO genotypes (OO, AO, AA, AB, BO, and BB) in 1,534 cases and 1,583 controls from 12 prospective cohorts in PanScan, grouping participants by genotype-derived serologic blood type (O, A, AB, and B). Adjusted odds ratios (ORs) for pancreatic cancer by ABO alleles were calculated using l...
Keywords: Pancreatic Cancer; Abo Blood Group; Prospective Cohort Study
Related Studies: 214, M4

Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer

Laufey Amundadottir et al., 2009/8 PubMed #19648918 MSID: 936
We conducted a two-stage genome-wide association study of pancreatic cancer, a cancer with one of the lowest survival rates worldwide. We genotyped 558,542 SNPs in 1,896 individuals with pancreatic cancer and 1,939 controls drawn from 12 prospective cohorts plus one hospital-based case-control study. We conducted a combined analysis of these groups plus an additional 2,457 affected individuals and 2,654 controls from eight case-control studies, adjusting for study, sex, ancestry and five princip...
Keywords: None Provided
Related Studies: 214, M4

Leukocyte telomere length, genetic variants at the TERT gene region and risk of pancreatic cancer

Ying Bao et al., 2017/6 PubMed #27797938 MSID: 1175
OBJECTIVE: Telomere shortening occurs as an early event in pancreatic tumorigenesis, and genetic variants at the telomerase reverse transcriptase (TERT) gene region have been associated with pancreatic cancer risk. However, it is unknown whether prediagnostic leucocyte telomere length is associated with subsequent risk of pancreatic cancer. DESIGN: We measured prediagnostic leucocyte telomere length in 386 pancreatic cancer cases and 896 matched controls from five prospective US cohorts. Ors and...
Keywords: Pancreatic Cancer; Inflammation; Telomere Length; Cohort Collaborative; Prospective Cohort Study
Related Studies: 214

Plasma 25-Hydroxyvitamin D and risk of pancreatic cancer

Brian Wolpin et al., 2011/11 PubMed #22086883 MSID: 1182
Laboratory studies suggest that vitamin D may inhibit pancreatic cancer cell growth. However, epidemiologic studies of vitamin D and pancreatic cancer risk have been conflicting.To determine whether prediagnostic levels of plasma 25-hydroxyvitamin D (25[OH]D; IDS Inc.; enzyme immunoassay) were associated with risk of pancreatic cancer, we conducted a pooled analysis of nested case-control studies with 451 cases and 1,167 controls from five cohorts through 2008. Median follow-up among controls wa...
Keywords: Pancreatic Cancer; Cohort Collaborative; Prospective Cohort Study; Vitamin D
Related Studies: 214

A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33

Gloria Petersen et al., 2010/1 PubMed #20101243 MSID: 1075
We conducted a genome-wide association study of pancreatic cancer in 3,851 affected individuals (cases) and 3,934 unaffected controls drawn from 12 prospective cohort studies and 8 case-control studies. Based on a logistic regression model for genotype trend effect that was adjusted for study, age, sex, self-described ancestry and five principal components, we identified eight SNPs that map to three loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Two correlated SNPs, rs9543325 (P = 3.27 x 10(-1...
Keywords: None Provided
Related Studies: 214, M4

Helicobacter pylori seropositivity, ABO blood type, and pancreatic cancer risk from five prospective cohorts

Approved Manuscript, Wolpin, Brian et al., 2022/4 MSID: 1405
Keywords: Pancreatic Cancer; Helicobacter Pylori; Cohort Collaborative; Prospective Cohort Study
Related Studies: 214

Hyperglycemia, insulin resistance, impaired pancreatic ß-cell function, and risk of pancreatic cancer

Brian Wolpin et al., 2013/7 PubMed #23847240 MSID: 1406
Obesity and diabetes mellitus are associated with an increased risk of pancreatic cancer. These associations may be secondary to consequences of peripheral insulin resistance, pancreatic ß-cell dysfunction, or hyperglycemia itself. Hemoglobin A1c (HbA1c) is a measure of hyperglycemia, whereas plasma insulin and proinsulin are markers of peripheral insulin resistance, and the proinsulin to insulin ratio marks pancreatic ß-cell dysfunction.This was a prospective, nested case-control study of 449 c...
Keywords: Pancreatic Cancer; C-Peptide; Insulin; Proinsulin; Hemoglobin A1c; Cohort Collaborative; Prospective Cohort Study
Related Studies: 214

Pancreatic cancer risk associated with prediagnostic plasma levels of leptin and leptin receptor genetic polymorphisms

Ana Babic et al., 2016/12 PubMed #27780823 MSID: 1407
Leptin is an adipokine involved in regulating energy balance, which has been identified as a potential biologic link in the development of obesity-associated cancers, such as pancreatic cancer. In this prospective, nested case-control study of 470 cases and 1,094 controls from five U.S. cohorts, we used conditional logistic regression to evaluate pancreatic cancer risk by prediagnostic plasma leptin, adjusting for race/ethnicity, diabetes, body mass index, physical activity, plasma C-peptide, ad...
Keywords: Pancreatic Cancer; Leptin; Cohort Collaborative; Prospective Cohort Study
Related Studies: 214

A prospective study of plasma adiponectin and pancreatic cancer risk in 5 US Cohorts

Ying Bao et al., 2012/12 PubMed #23243202 MSID: 1408
The adipocyte-secreted hormone adiponectin has insulin-sensitizing and anti-inflammatory properties. Although development of pancreatic cancer is associated with states of insulin resistance and chronic inflammation, the mechanistic basis of the associations is poorly understood.To determine whether prediagnostic plasma levels of adiponectin are associated with risk of pancreatic cancer, we conducted a nested case-control study of 468 pancreatic cancer case subjects and 1080 matched control subj...
Keywords: Pancreatic Cancer; Adiponectin; Cohort Collaborative; Prospective Cohort Study
Related Studies: 214

Inflammatory plasma markers and pancreatic cancer risk: a prospective study of five U.S. cohorts

Ying Bao et al., 2013/5 PubMed #23462920 MSID: 1837
Chronic inflammation may play a role in the development of pancreatic cancer. However, few prospective studies have examined the association between plasma inflammatory markers and pancreatic cancer risk. Therefore, we investigated the association of prediagnostic circulating C-reactive protein (CRP), interleukin-6 (IL-6), and TNF-a receptor II (TNF-aR2) with subsequent pancreatic cancer risk in a prospective, nested case-control study of 470 cases and 1,094 controls from Health Professionals Fo...
Keywords: Pancreatic Cancer; C-Reactive Protein; Interleukin-6; Tumor Necrosis Factor-A-Receptor Ii; Cohort Collaborative; Prospective Cohort Study
Related Studies: 214

Plasma metabolite profiling and risk of pancreatic adenocarcinoma

Approved Proposal, Wu, Cindy et al., 2012/11 MSID: 1974
Keywords: Pancreatic Cancer; Metabolomics; Metabolite Profiles; Cohort Collaborative; Prospective Cohort Study
Related Studies: 214

Circulating metabolites and survival among patients with pancreatic cancer

Chen Yuan et al., 2016/1 PubMed #26755275 MSID: 2637
BACKGROUND: Pancreatic tumors cause changes in whole-body metabolism, but whether prediagnostic circulating metabolites predict survival is unknown. METHODS: We measured 82 metabolites by liquid chromatography-mass spectrometry in prediagnostic plasma from 484 pancreatic cancer case patients enrolled in four prospective cohort studies. Association of metabolites with survival was evaluated using Cox proportional hazards models adjusted for age, cohort, race/ethnicity, cancer stage, fasting time,...
Keywords: Pancreatic Cancer; Metabolomics; Metabolite Profiles; Cohort Collaborative; Prospective Cohort Study. Survival
Related Studies: 214

Prediagnostic plasma 25-hydroxyvitamin D and pancreatic cancer survival

Chen Yuan et al., 2016/6 PubMed #27325858 MSID: 2642
PURPOSE: Although vitamin D inhibits pancreatic cancer proliferation in laboratory models, the association of plasma 25-hydroxyvitamin D [25(OH)D] with patient survival is largely unexplored. PATIENTS AND METHODS: We analyzed survival among 493 patients from five prospective US cohorts who were diagnosed with pancreatic cancer from 1984 to 2008. We estimated hazard ratios (HRs) for death by plasma level of 25(OH)D (insufficient, < 20 ng/mL; relative insufficiency, 20 to < 30 ng/mL; sufficient = ...
Related Studies: 214

Prediagnostic leukocyte telomere length and pancreatic cancer survival

Tsuyoshi Hamada et al., 2019/8 PubMed #31427306 MSID: 3604
BACKGROUND: Leukocyte telomere length has been associated with risk of subsequent pancreatic cancer. Few prospective studies have evaluated the association of prediagnostic leukocyte telomere length with pancreatic cancer survival. METHODS: We prospectively examined the association of prediagnostic leukocyte telomere length with overall survival (OS) time among 423 participants diagnosed with pancreatic adenocarcinoma between 1984 and 2008 within the Health Professionals Follow-up Study, Nurses'...
Keywords: Biomarkers; Epidemiology; Pancreatic Neoplasms; Survival Analysis; Telomere Shortening
Related Studies: 214

Genetic and circulating biomarker data improve risk prediction for pancreatic cancer in the general population

Approved Manuscript, Kim, Jihye et al., 2018/10 MSID: 3605
Keywords: Pancreatic Cancer; Biomarkers; Genetic Risk Score; Risk Prediction; Cumulative Absolute Risk; And 10-Year Absolute Risk
Related Studies: 214

Prediagnostic inflammation and pancreatic cancer survival

Approved Manuscript, Yuan, Chen et al., 2019/11 MSID: 3799
Keywords: Pancreatic Cancer; Plasma Inflammatory Biomarkers; Cohort Collaborative; Prospective Cohort Study; Survival
Related Studies: 214

Prediagnostic circulating levels of adipokines and survival of patients with pancreatic cancer

Approved Proposal, Babic, Ana et al., 2020/6 MSID: 4219
Keywords: Pancreatic Cancer; Leptin; Adiponectin; Prospective Cohort Study; Survival
Related Studies: 214